French Lung Cancer Group Report issue

Foundation Phase 2

Organization Overview

First Clinical Trial
2018
NCT03669523
First Marketed Drug
None
First NDA Approval
None
Last Known Activity
2019

Timeline

NOW
  • Now

Alternative names

French Lung Cancer Group | GFPC

Indications

Experimental Indications (Clinical Trials, Phases 1-4)


 

Bone Marrow Diseases (Phase 2)

Bone Neoplasms (Phase 2)

Carcinoma, Non-Small-Cell Lung (Phase 2)

Neoplasm Metastasis (Phase 2)

Overview

  • Highest Phase: Phase 2
  • # of Trials: 2
  • # of Trial APIs: 6